Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer

BACKGROUND: First-line treatment with nivolumab plus ipilimumab (N+I) or nivolumab plus ipilimumab with two cycles of chemotherapy (N+I+chemotherapy) improve overall survival and progression-free survival for patients with metastatic non-small cell lung cancer (NSCLC), yet researchers have not conco...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Szu-Chun, Kunst, Natalia, Gross, Cary P., Wang, Jung-Der, Su, Wu-Chou, Wang, Shi-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695441/
https://www.ncbi.nlm.nih.gov/pubmed/34956882
http://dx.doi.org/10.3389/fonc.2021.760686

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695441/
https://www.ncbi.nlm.nih.gov/pubmed/34956882
http://dx.doi.org/10.3389/fonc.2021.760686

Ejemplares similares